Adverse markers for progression19
| Variable* . | Adverse marker . | Points . |
|---|---|---|
| MGUS | ||
| M-spike isotype | IgA | 1 |
| M-spike concentration | ≥15 g/L | 1 |
| Serum FLC ratio (κ:λ) | <0.1 or >10 | 1 |
| Immunoparesis | Uninvolved immunoglobulins below lower level of normal | 1 or 2 |
| Light chain MGUS | ||
| Serum FLC ratio (κ:λ) | <0.1 or >10 | 1 |
| Immunoparesis | Uninvolved immunoglobulins below lower level of normal | 1, 2, or 3 |
| Variable* . | Adverse marker . | Points . |
|---|---|---|
| MGUS | ||
| M-spike isotype | IgA | 1 |
| M-spike concentration | ≥15 g/L | 1 |
| Serum FLC ratio (κ:λ) | <0.1 or >10 | 1 |
| Immunoparesis | Uninvolved immunoglobulins below lower level of normal | 1 or 2 |
| Light chain MGUS | ||
| Serum FLC ratio (κ:λ) | <0.1 or >10 | 1 |
| Immunoparesis | Uninvolved immunoglobulins below lower level of normal | 1, 2, or 3 |
Risk categories for progression to MM and light chain MM: 0 to 1, low-risk and low-risk light chain; 2, intermediate-risk and intermediate-risk light chain; 3 or higher, high-risk and high-risk light chain.